GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

Roivant Sciences ROIV · USD

Health Care · US listing · 🇺🇸 United States

Compare

40.67

+4.60%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2026

Revenue

$8.3m

FY2019FY2026

Net income

−$299.8m

FY2019FY2026

Free cash flow

−$758.6m

FY2019FY2026

Shareholders' equity

$4.53bn

FY2019FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue$8.3m$29.1m$32.7m$31.5m$55.3m$23.8m$67.7m$2.3m
Gross profit$7.0m$28.1m$31.1m$28.5m$46.3m$21.7m$66.6m$1.7m
Research and development$681.8m$550.4m$439.9m$454.1m$483.0m$236.6m$263.2m$513.0m
Operating income−$1.29bn−$1.11bn−$824.9m−$809.0m−$917.1m−$895.7m−$532.4m−$748.5m
Net income−$299.8m−$172.0m$4.35bn−$1.01bn−$845.3m−$809.2m$1.20bn−$1.04bn
Diluted earnings per share-0.42-0.256.02-1.19-1.18-1.181.75-4.84

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Total assets$5.73bn$5.44bn$7.22bn$2.39bn$2.59bn$2.69bn$2.48bn$1.39bn
Cash and short-term investments$4.30bn$4.89bn$6.54bn$1.68bn$2.06bn$2.13bn$2.19bn$849.6m
Total liabilities$435.6m$249.7m$774.0m$782.0m$523.7m$527.7m$368.4m$450.5m
Debt$11.1m—$442.6m$421.9m$210.0m$170.3m$108.6m$108.6m
Shareholders' equity$4.53bn$4.69bn$5.97bn$1.16bn$1.66bn$1.90bn$2.03bn$937.3m
Shares outstanding721m697m723m844m713m687m685m215m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations−$750.3m−$839.5m−$765.3m−$843.4m−$677.7m−$552.1m−$761.8m−$1.02bn
Capital spending−$8.2m−$4.6m−$1.4m−$12.7m−$17.4m−$5.8m−$4.9m−$11.4m
Free cash flow−$758.6m−$844.1m−$766.6m−$856.1m−$695.2m−$557.9m−$766.7m−$1.04bn
Dividends paid——−$6.0m−$162.7m————

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$1.4m$2.5m$2.0m$1.6m$2.2m$7.6m$9.0m$4.5m
Gross profit$1.2m$2.2m$1.3m$1.5m$2.0m$7.4m$8.8m$4.2m
Operating income−$366.0m−$355.0m−$339.2m−$306.2m−$284.9m−$285.0m−$274.4m−$341.7m
Net income−$189.8m$303.0m−$265.9m−$113.5m−$223.4m−$206.5m$169.4m−$230.2m
Diluted earnings per share-0.260.42-0.38-0.16-0.32-0.300.23-0.32
Cash from operations−$263.0m−$163.0m−$196.0m−$185.0m−$204.0m−$172.0m−$207.0m−$266.0m
Capital spending—−$1.0m−$4.0m−$7.0m−$4.0m—−$1.0m—
Free cash flow—−$164.0m−$200.0m−$192.0m−$208.0m—−$208.0m—
Total assets$5.31bn$5.73bn$5.23bn$5.06bn$5.03bn$5.44bn$5.79bn$6.21bn
Cash and short-term investments$3.84bn$4.30bn$4.53bn$4.39bn$4.50bn$4.89bn$5.15bn$5.39bn
Debt$12.4m$11.1m$10.4m$9.0m$9.4m$9.8m$9.8m$9.5m
Shareholders' equity$4.23bn$4.53bn$4.27bn$4.36bn$4.35bn$4.69bn$5.19bn$5.15bn

Financial ratios

Data as of 28 Sept 2026

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Gross margin84.4%96.9%95.1%90.4%83.8%91.4%——
Operating margin-15560.6%-3833.3%-2521.7%-2565.9%-1658.8%-3764.4%——
Net margin-3629.2%-592.0%13294.2%-3200.2%-1528.9%-3400.9%——
Return on equity-6.6%-3.7%72.9%-87.2%-51.0%-42.6%——
Return on assets-5.2%-3.2%60.2%-42.2%-32.7%-30.1%——
Free cash flow yield-2.9%-3.3%-3.0%-2.7%-2.6%-2.2%——
Revenue growth-71.6%-11.2%3.8%-43.0%132.3%-64.8%——
Earnings growth74.3%-104.0%-531.0%19.4%4.5%-167.4%——
Current ratio18.37x33.47x25.24x6.60x11.64x9.99x——
Debt to equity0.00x0.00x0.08x0.37x0.13x0.10x——
Equity ratio79.0%86.2%82.6%48.5%64.1%70.6%——
Interest coverage——-23.72x-28.93x-130.25x-318.88x-69.30x-80.99x
R&D as a share of sales8254.4%1894.5%1344.8%1440.1%873.7%994.4%——
Buybacks as a share of market value-3.4%3.6%14.4%-18.4%-3.9%-0.3%——

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-36.0%-19.1%—
Operating income16.7%7.5%—
Net income-33.3%-18.0%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin94.1%93.3%90.1%—
Operating margin-6429.4%-3971.1%-3236.2%—
Net margin-1264.3%2824.2%671.9%—

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Price to earnings-91.9-87.92.0-9.4-6.7-8.65.8
Price to sales——261.4300.8103.1290.9102.9

Market value over time

31 Dec 2020 to 25 Sept 2026, in USD

$6.41bn$25.80bn

Share price return

Finished calendar years

202520242023202220212020
Return86%8%64%-51%35%-4%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 1-to-1 reverse split · 1 Oct 2021

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.